9 completed, 3 not yet recruiting, 2 withdrawn, 1 active not recruiting. 6 Phase 1, 5 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Not yet recruiting 2, Withdrawn 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Not applicable | 2 | Completed 2 |
Follow Hereditary Hemorrhagic Telangiectasia (HHT): new trials by email Literature Review of Hereditary Hemorrhagic Telangiectasia (HHT) trials Research Report on Hereditary Hemorrhagic Telangiectasia (HHT)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT) TX002100 - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 | Not yet recruiting | Tectonic Operating Company, Inc. | 20 | 2026-12-31 | 2026-10-15 |
| Topical TOR-582 Treatment of Epistaxis in HHT Topical sirolimus ointment - Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis | Phase 1 | Not yet recruiting | Columbia University | 27 | 2026-10-01 | 2026-08-21 |
| Prevalence of Obstructive Sleep Apnea in HHT and HHT-specific Challenges in OSA-therapy - a Retrospective Cohort Study Hereditary Hemorrhagic Telangiectasia (HHT), Obstructive Sleep Apnea (OSA) | Not yet recruiting | University Hospital, Essen | 1000 | 2026-10-01 | 2026-10-21 | |
| Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) ATV-1601, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease | Phase 1 / Phase 2 | Recruiting | Atavistik Bio, Inc | 100 | 2026-07-27 | 2026-10-05 |
| A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia TER-1754, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 | Withdrawn | Terremoto Biosciences Inc. | 2025-12-15 | 2026-04-13 | |
| Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network Bevacizumab - Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension | Enrolling by invitation | Poitiers University Hospital | 111 | 2025-10-15 | 2026-03-03 | |
| Description of the Impact of Symptoms on Quality of Life in HHT Disease: DISQUO completion of the QOL-HHT questionnaire - Hereditary Hemorrhagic Telangiectasia (HHT) | Completed | Hospices Civils de Lyon | 185 | 2024-12-01 | 2025-09-25 | |
| Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study Pomalidomide - Hereditary Hemorrhagic Telangiectasia (HHT) | Completed | Massachusetts General Hospital | 62 | 2024-05-01 | 2026-07-10 | |
| Assess Safety and Efficacy of VAD044 in HHT Patients VAD044 Part I, VAD044 Part II - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 / Phase 2 | Active not recruiting | Vaderis Therapeutics AG | 75 | 2022-07-18 | 2026-03-17 |
| Doxycycline for Hereditary Hemorrhagic Telangiectasia Doxycycline Hyclate, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 2 | Completed | Unity Health Toronto | 13 | 2018-09-12 | 2025-04-01 |
| Graded TTCE for Post-Embolization PAVM Monitoring Transthoracic Contrast Echocardiogram - Hereditary Hemorrhagic Telangiectasia (HHT) | Completed | University of Pennsylvania | 32 | 2016-10-01 | 2019-11-08 | |
| Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT) Floseal, Packing - Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis | Not applicable | Completed | Unity Health Toronto | 8 | 2015-12-01 | 2020-05-28 |
| Frequency of Common Medical Conditions in People With and Without HHT Questionnaire - Hereditary Hemorrhagic Telangiectasia (HHT) | Not applicable | Completed | Imperial College London | 2174 | 2012-04-01 | 2023-09-28 |
| Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) Ranibizumab - Hereditary Hemorrhagic Telangiectasia (HHT), Nosebleeds | Phase 1 | Withdrawn | University of California, San Diego | 2011-07-01 | 2013-04-29 | |
| Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) Submucosal Bevacizumab - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 2 | Completed | University of California, San Diego | 10 | 2010-07-22 | 2019-12-04 |
| Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) Bevacizumab - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 2 | Completed | University of California, San Diego | 20 | 2009-06-01 | 2019-09-06 |
| IV Bevacizumab Treatment of Patients With Hereditary Hemorrhagic Telangiectasia (HHT) or Rendu-Osler (RO) Disease: A Retrospective Analysis of French Cohort Data From 2009 to 2024 Real World data study. - Hereditary Hemorrhagic Telangiectasia (HHT), Rendu Osler Disease | Completed | Hospices Civils de Lyon | 244 | 2009-01-01 | 2026-08-19 |
Telangiectasia, Hereditary Hemorrhagic (17) · Epistaxis (5) · Arteriovenous Malformations (3) · Anemia (2) · Vascular Malformations (2) · Cardiac Output, High (1) · Cardiovascular Diseases (1) · Disease (1) · Hematologic Diseases (1) · Hemorrhage (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Hypertension, Pulmonary (1) · Pulmonary Arteriovenous Fistulas (1) · Sleep Apnea, Obstructive (1)
Cardiovascular Abnormalities (17) · Congenital Abnormalities (17) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17) · Hemic and Lymphatic Diseases (17) · Cardiovascular Diseases (16) · Hematologic Diseases (16) · Hemorrhagic Disorders (16) · Hemostatic Disorders (16) · Telangiectasis (16) · Vascular Diseases (16) · Vascular Malformations (15) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Respiratory Tract Diseases (7) · Signs and Symptoms (6)
Bevacizumab (3) · Capsules (2) · Confidentiality (1) · Doxycycline (1) · Drug Packaging (1) · FloSeal Matrix (1) · Ranibizumab (1) · Surveys and Questionnaires (1) · pomalidomide (1)
University of California, San Diego (3) · Hospices Civils de Lyon (2) · Unity Health Toronto (2) · Atavistik Bio, Inc (1) · Columbia University (1) · Imperial College London (1) · Massachusetts General Hospital (1) · Poitiers University Hospital (1) · Tectonic Operating Company, Inc. (1) · Terremoto Biosciences Inc. (1) · University Hospital, Essen (1) · University of Pennsylvania (1) · Vaderis Therapeutics AG (1)
United States (8) · France (4) · Canada (2) · Belgium (1) · Italy (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
Terence Davidson, M.D. (2) · Claire L Shovlin, PhD MB BChir FRCP (1) · Damien Picard (1) · Ellen Zhang, MD (1) · John Lee, MD, MSc (1) · Marie E Faughnan, MD MSc FRCPC (1) · Scott O Trerotola, MD (1)
PMID 23404156, PMID 23445111, PMID 24146883, PMID 24354965, PMID 24458873, PMID 27107394, PMID 27116331, PMID 27727478, PMID 27730189, PMID 27837281, PMID 31615556, PMID 31794700, PMID 36344987, PMID 41297007, PMID 41512167